CEO Gail Boudreaux bought 8,500 shares for $2,438,951.30 at $286.94 (blended) as ELV stock down 26.3% in 30 days, 34.7% in 90 days.
On 2025-07-18, Elevance Health CEO Gail Boudreaux executed 3 open-market purchases totaling 8,500 shares for $2,438,951.30 at a blended average price of $286.94, increasing her holdings from 142,520 to 151,020 shares. The timing is notable: the stock has declined 26.3% in the prior 30 days and 34.7% in the prior 90 days from a 52-week high of $562.29, now trading at $277.09—a 3% discount to the transaction price. This is Boudreaux's first open-market buy activity flagged in the filing; her prior 5 trades at ELV (all in July 2024) were sales, and her cross-ticker track record of 6 prior sales achieved a 100% well-timed rate (all 5 same-ticker sales were followed by stock declines). The Company itself remains fundamentally solid with $49.8B in annual revenue, $1.7B net income, and a 11.64 P/E ratio, suggesting the recent selloff may have created a valuation opportunity. The divergence between the insider's historical pattern (well-timed exits) and this discretionary buy into a steep drawdown warrants attention to whether this signals a shift in conviction or is simply a redeployment of capital at compressed valuations.